AUSTIN, Texas and MINNEAPOLIS, Oct. 20,
2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and
Bio-Techne Corp (NASDAQ: TECH) today announced the signing of a new
distribution and supply agreement through 2020. This agreement
extends the relationship between the two companies for immunoassay
development and commercialization of Bio-Techne biological content
using the Luminex testing platform. Furthermore the agreement
allows Bio-Techne to distribute Luminex multiplexing
instrumentation, including the Luminex™ 200®, FLEXMAP 3D® and the
MAGPIX® platforms in major markets worldwide.
![Luminex logo Luminex logo](http://photos.prnewswire.com/prnvar/20150201/172702LOGO)
"We are very pleased to broaden our relationship with
Bio-Techne, a leading global player in the research, diagnostics
and clinical controls markets. We believe enabling Bio-Techne to
develop assay content and distribute Luminex multiplexing
instruments will aid our goal of providing laboratories of all
sizes access to multiplexing solutions for a range of
applications," said Todd Bennett, VP, Global Sales and
Customer Operations, Luminex Corporation. "With its global scope,
Bio-Techne is an ideal partner that can ensure our advanced
multiplexing solutions reach the right scientists and researchers.
This partnership will help accelerate science and improve the
efficiency of disease-related research around the world."
"We have been a partner with Luminex for many years and given
our strong market position in immunoassay applications, it is
logical for Bio-Techne to continue to support our customers with
complete customized workflow solutions, including instruments. This
is consistent with the Company's strategic direction of providing
full solutions in the Life Science research space, including both
biological content and instruments," said Gerry Andros, VP of Sales for Bio-Techne
Corporation.
Financial terms were not disclosed.
About xMAP-based Instruments
Luminex offers three multiplex instruments enabling laboratories
to choose a platform that fits their throughput and flexibility
needs. MAGPIX is the simplest, most affordable, and most compact of
Luminex's xMAP instruments. This compact multiplexing unit performs
up to 50 different tests in a single reaction volume and reads a
96-well plate in just 60 minutes. The Luminex 200 System provides
laboratorians the ability to perform up to 100 different tests in a
single reaction volume while using either magnetic or polystyrene
microspheres. FLEXMAP 3D is the platform of choice for high
throughput applications. The platform is capable of simultaneously
measuring up to 500 genes or proteins from a small sample. All
three xMAP-based instruments run multiplexed assays for both
proteins and nucleic acids, whether kit-based or lab-developed.
Learn more about Luminex instruments:
www.luminexcorp.com/instruments
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward creating breakthrough solutions to improve health and
advance science. The company is transforming global healthcare and
life-science research through the development, manufacturing and
marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte platform, MultiCode® real-time
polymerase chain reaction (PCR), and multiplex PCR-based
technologies, that deliver cost-effective rapid results to
clinicians and researchers. Luminex's technologies are commercially
available worldwide and in use in leading clinical laboratories, as
well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. Luminex is meeting the needs of customers
in markets as diverse as clinical diagnostics, pharmaceutical drug
discovery, biomedical research including genomic and proteomic
research, personalized medicine, biodefense research and food
safety. For further information on Luminex Corporation and the
latest advances in multiplexing using award winning technology,
please visit http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward- looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, including ARIES and related assays, and the regulatory
approvals thereof. The words "believe", "expect", "intend",
"anticipates", "confident", "will", "could", "should", and
similar expressions are intended to further identify such
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially
from those anticipated in such forward-looking statements. Factors
that could cause Luminex's actual results or performance to differ
materially include risks and uncertainties relating to, among
others, our ability to launch products on time, the timing of
regulatory approvals, the outcome of clinical trials as well as the
risks discussed under the heading "Risk Factors" in Luminex's
Reports on Forms 10-K and 10-Q, as filed with the Securities and
Exchange Commission. The forward looking statements contained
herein represent the judgment of Luminex as of the date of this
press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
About Bio-Techne Corp
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $452
million in net sales in fiscal 2015 and has approximately
1,500 employees worldwide. For more information on Bio-Techne and
its brands, please visit www.bio-techne.com.
Our press releases may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act.
Such statements involve risks and uncertainties that may affect the
actual results of operations. The following important factors,
among others, have affected and, in the future, could affect the
Company's actual results: the effect of new branding and marketing
initiatives, the integration of new leadership, delays or obstacles
in integrating acquired companies, the introduction and acceptance
of new biotechnology and clinical control products, the levels and
particular directions of research by the Company's customers, the
impact of the growing number of producers of biotechnology research
products and related price competition, general economic
conditions, the impact of currency exchange rate fluctuations, and
the costs and results of research and product development efforts
of the Company and of companies in which the Company has invested
or with which it has formed strategic relationships. For
additional information concerning such factors, see the section
titled "Risk Factors" in the Company's annual report on Form 10-K
and quarterly reports on Form 10-Q as filed with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statements we make in our press releases due to
new information or future events. Investors are cautioned not to
place undue emphasis on these statements.
Bio-Techne Contact
Jim
Hippel
CFO and Investor Relations
612-656-4472
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
Logo - http://photos.prnewswire.com/prnh/20151019/278495LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-and-bio-techne-corporation-extend-and-expand-partnership-300162428.html
SOURCE Luminex Corporation; Bio-Techne Corporation